Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide alone and with rituximab for primary central nervous system lymphoma
ChiCTR2100053250Phase 2Recruiting
- Sponsor
- Second Hospital of Lanzhou University
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pomalidomide and rituximab in primary central nervous system lymphoma (PCNSL) (2 arms), sponsored by Second Hospital of Lanzhou University. Primary endpoint: Objective response rate. Started Dec 2021; status: recruiting.
02
Drugs
pomalidomiderituximab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on ChiCTR2100053250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053250.